1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Generics in the United States, MarketLine

Generics in the United States, MarketLine

  • January 2016
  • -
  • MarketLine
  • -
  • 34 pages

Introduction

Generics in the United States industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2011-15, and forecast to 2020). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the United States generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Highlights

- For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.

- The US generics market is expected to generate total revenues of $94.0bn in 2015, representing a compound annual growth rate (CAGR) of 6.4% between 2011 and 2015.

- Market consumption volume is forecast to reach a total of 89.8% of total pharma volume in 2015.

- In the US, generic drugs have led to annual savings of $254bn in 2014. This has grown consistently in the last decade: in 2005, generic drug savings were $87bn. Total savings in the last 10 years have reached a total of $1.68 trillion.

Features

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in the United States

- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in the United States

- Leading company profiles reveal details of key generics market players’ global operations and financial performance

- Add weight to presentations and pitches by understanding the future growth prospects of the United States generics market with five year forecasts by both value and volume

- Macroeconomic indicators provide insight into general trends within the United States economy

Key Questions Answered

- What was the size of the United States generics market by value in 2015?

- What will be the size of the United States generics market in 2020?

- What factors are affecting the strength of competition in the United States generics market?

- How has the market performed over the last five years?

- How large is the United States’s generics market in relation to its regional counterparts?

Table Of Contents

Generics in the United States, MarketLine
TABLE OF CONTENTS
Executive Summary 2
Market value 2
Market value forecast 2
Market volume 2
Market volume forecast 2
Geography segmentation 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market volume 9
Market Segmentation 10
Geography segmentation 10
Market Outlook 11
Market value forecast 11
Market volume forecast 12
Five Forces Analysis 13
Summary 13
Buyer power 14
Supplier power 15
New entrants 16
Threat of substitutes 17
Degree of rivalry 18
Leading Companies 19
Allergan plc 19
Mylan Inc. 22
Sandoz International GmbH 25
Teva Pharmaceutical Industries Limited 26
Macroeconomic Indicators 29
Country Data 29
Methodology 31
Industry associations 32
Related MarketLine research 32
Appendix 33
About MarketLine 33

List of Tables
Table 1: United States generics market value: $ billion, 2011-15(e)
Table 2: United States generics market volume: % of total pharma volume, 2011-15(e)
Table 3: United States generics market geography segmentation: $ billion, 2015(e)
Table 4: United States generics market value forecast: $ billion, 2015-20
Table 5: United States generics market volume forecast: % of total pharma volume, 2015-20
Table 6: Allergan plc: key facts
Table 7: Allergan plc: key financials ($)
Table 8: Allergan plc: key financial ratios
Table 9: Mylan Inc.: key facts
Table 10: Mylan Inc.: key financials ($)
Table 11: Mylan Inc.: key financial ratios
Table 12: Sandoz International GmbH: key facts
Table 13: Teva Pharmaceutical Industries Limited: key facts
Table 14: Teva Pharmaceutical Industries Limited: key financials ($)
Table 15: Teva Pharmaceutical Industries Limited: key financial ratios
Table 16: United States size of population (million), 2011-15
Table 17: United States gdp (constant 2005 prices, $ billion), 2011-15
Table 18: United States gdp (current prices, $ billion), 2011-15
Table 19: United States inflation, 2011-15
Table 20: United States consumer price index (absolute), 2011-15
Table 21: United States exchange rate, 2011-15

List of Figures
Figure 1: United States generics market value: $ billion, 2011-15(e)
Figure 2: United States generics market volume: % of total pharma volume, 2011-15(e)
Figure 3: United States generics market geography segmentation: % share, by value, 2015(e)
Figure 4: United States generics market value forecast: $ billion, 2015-20
Figure 5: United States generics market volume forecast: % of total pharma volume, 2015-20
Figure 6: Forces driving competition in the generics market in the United States, 2015
Figure 7: Drivers of buyer power in the generics market in the United States, 2015
Figure 8: Drivers of supplier power in the generics market in the United States, 2015
Figure 9: Factors influencing the likelihood of new entrants in the generics market in the United States, 2015
Figure 10: Factors influencing the threat of substitutes in the generics market in the United States, 2015
Figure 11: Drivers of degree of rivalry in the generics market in the United States, 2015
Figure 12: Allergan plc: revenues and profitability
Figure 13: Allergan plc: assets and liabilities
Figure 14: Mylan Inc.: revenues and profitability
Figure 15: Mylan Inc.: assets and liabilities
Figure 16: Teva Pharmaceutical Industries Limited: revenues and profitability
Figure 17: Teva Pharmaceutical Industries Limited: assets and liabilities

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.